poisar

Stocks · News reference

Goldman Sachs Initiates Coverage On Zoetis with Neutral Rating, Announces Price Target of $74

Benzinga Newsdesk

Goldman Sachs analyst Matt Dellatorre initiates coverage on Zoetis (NYSE:ZTS) with a Neutral rating and announces Price Target of $74.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ZTS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Zoetis Inc. (ZTS)

    Filed: 2026-10-13 AccNo: 0001555280-26-000044 Size: 225 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    ZTS
  2. Na

    Is it the Right Time to Add Phibro Stock to Your Portfolio?

    Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results.

    PAHCZTSVCYTABTGMED